Viridian receives FDA approval for Lumvoa, first TED therapy covering active and chronic disease

Filed June 29, 2026 · Period ending June 26, 2026 · ~1 min read

Key Changes

• high

  FDA approved Lumvoa for thyroid eye disease treatment regardless of activity or duration, making it the first approved TED therapy with labeling covering both active and chronic disease forms.

  Item 8.01 — Other Events verify on EDGAR →
• high

  Viridian launching Lumvoa immediately with prescriptions available next day; marks company's transition from development to commercial stage.

  Exhibit 99.1 verify on EDGAR →
• high

  Pivotal THRIVE trials met all primary and secondary endpoints with clinical benefits appearing as early as three weeks; Lumvoa first approved TED product showing statistically significant effects on diplopia in both active and chronic disease.

  Exhibit 99.1 verify on EDGAR →